Technical Analysis for CCXI - ChemoCentryx, Inc.

Grade Last Price % Change Price Change
F 47.18 1.88% 0.87
CCXI closed up 1.88 percent on Tuesday, April 13, 2021, on 1.13 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical CCXI trend table...

Date Alert Name Type % Chg
Jack-in-the-Box Bearish Bearish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Inside Day Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
Expansion Breakdown Bearish Swing Setup 1.88%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.88%
Reversal New Lows Setup Bearish Swing Setup 1.88%
Outside Day Range Expansion 1.88%
Oversold Stochastic Weakness 1.88%
Outside Day Range Expansion -4.51%
Older End-of-Day Signals for CCXI ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakdown about 9 hours ago
Up 3% about 12 hours ago
Up 2% about 12 hours ago
Up 1% about 12 hours ago
Down 5% 1 day ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

ChemoCentryx, Inc. Description

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer in the United States. Its drug candidates under clinical stage include Vercirnon, which is in Phase III clinical trials for the treatment of patients with moderate-to-severe Crohn's disease; CCX140 that is in Phase II clinical trials for the treatment of patients with diabetic nephropathy, a form of kidney disease; and CCX354 that completed a Phase II proof-of-concept clinical trial for the treatment of rheumatoid arthritis. The company's drug candidates also comprise CCX168, which is in a Phase II clinical trial for the treatment of anti-neutrophil cytoplasmic antibody associated vasculitis; CCX872 that is under Phase I clinical development targeting CCR2 for expanded indications of renal disease; and CCX507, a de novo wholly-owned CCR9 inhibitor, which is in Phase I clinical trials for inflammatory bowel disease and related disorders. Its preclinical stage programs comprise CCX650, an orally active drug for the treatment of glioblastoma multiforme; CCR4 inhibitor for atopic dermatitis; CCX6239, an orally administered CCR4 antagonist with potential utility in the treatment of atopic dermatitis, an inflammatory disease; CCR6 inhibitor for autoimmune diseases; and CXCR6 inhibitor for chronic hepatitis. ChemoCentryx, Inc. has a strategic alliance with Glaxo Group Limited for the discovery and development of small molecule antagonists targeting four defined chemokine and chemo-attractant receptor targets and for advancing them through clinical proof-of-concept. The company was founded in 1997 and is headquartered in Mountain View, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Immunology Clinical Development Autoimmune Diseases Monoclonal Antibodies Autoimmune Disease Inflammatory Disease Rheumatoid Arthritis Kidney Disease Blastoma Inflammatory Bowel Disease Glioblastoma Dermatitis Renal Disease Atopic Dermatitis Diabetic Nephropathy Immunosuppressants Related Disorders Inflammatory Disorders Biotie Therapies Glioblastoma Multiforme Chronic Hepatitis Janus Kinase Inhibitor Vasculitis

Is CCXI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 70.22
52 Week Low 44.68
Average Volume 433,585
200-Day Moving Average 56.67
50-Day Moving Average 58.14
20-Day Moving Average 51.53
10-Day Moving Average 49.04
Average True Range 2.86
ADX 28.05
+DI 10.91
-DI 24.59
Chandelier Exit (Long, 3 ATRs ) 51.01
Chandelier Exit (Short, 3 ATRs ) 54.57
Upper Bollinger Band 58.35
Lower Bollinger Band 44.71
Percent B (%b) 0.18
BandWidth 26.47
MACD Line -3.02
MACD Signal Line -2.91
MACD Histogram -0.1157
Fundamentals Value
Market Cap 3.27 Billion
Num Shares 69.2 Million
EPS -0.92
Price-to-Earnings (P/E) Ratio -51.12
Price-to-Sales 50.29
Price-to-Book 9.54
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 50.13
Resistance 3 (R3) 50.11 49.11 49.64
Resistance 2 (R2) 49.11 48.35 49.12 49.48
Resistance 1 (R1) 48.14 47.89 48.62 48.16 49.31
Pivot Point 47.14 47.14 47.38 47.15 47.14
Support 1 (S1) 46.17 46.38 46.66 46.20 45.05
Support 2 (S2) 45.17 45.92 45.18 44.88
Support 3 (S3) 44.20 45.17 44.72
Support 4 (S4) 44.23